Accendra Health gets NYSE notice over sub-$1 average

Accendra Health has six months to meet the NYSE’s $1.00 minimum-price test while its shares remain listed, subject to other listing standards.

Rhea-AI Filing Summary

Accendra Health (ACH) received a New York Stock Exchange notice on October 6, 2026, after its common stock’s average closing price was below $1.00 per share over a consecutive 30 trading-day period. The notice does not immediately affect the stock’s NYSE listing.

Accendra Health has six months after receiving the notice to regain compliance and intends to tell the NYSE within 10 business days that it will seek to cure the deficiency. It may regain compliance if, on the last trading day of a calendar month during the cure period or on its final day, the stock closes at least $1.00 and has an average closing price of at least $1.00 over the 30 trading-day period ending that day. The company is considering alternatives, including, if necessary, a reverse stock split subject to stockholder approval no later than its next annual meeting, anticipated in May 2027. Its stock remains listed during the period, subject to other NYSE continued listing standards.

0 points · 0 major

NegativeiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 1 point

How the balance works

Positive

• None.

Negative

• Moderate pointNYSE deficiency: average closing price was below $1.00 over 30 trading days.

Filing Explained

After the October 6 NYSE price notice, Accendra has six months to cure; one option under consideration is a stockholder-approved reverse split, which would proportionally reduce shares and raise the per-share price without itself changing company value.

8-K Event Classification

3 items: 3.01, 7.01, 9.01

3 items

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Minimum share price: $1.00 per share Price measurement period: 30 trading days Cure period: Six months +2 more

5 metrics

Minimum share price $1.00 per share NYSE continued listing requirement

Price measurement period 30 trading days Average closing price period

Cure period Six months Following receipt of the NYSE notice

Notice response deadline 10 business days To notify the NYSE of intent to cure

Anticipated annual meeting May 2027 Stockholder approval for a reverse split, if necessary, would be sought no later than this meeting

Key Terms

continued listing standard, cure period, reverse stock split, minimum share price requirement

4 terms

continued listing standard regulatory

"not in compliance with the continued listing standard"

Continued listing standards are the ongoing rules a stock exchange or trading venue requires a company to meet to keep its shares listed, such as minimum share price, market value, shareholder equity, and timely financial reporting. For investors, these standards matter because failure to meet them can trigger warnings or removal from the exchange, which can reduce a stock’s visibility, trading liquidity, and value—similar to how failing building inspections can limit a business’s ability to operate publicly.

cure period regulatory

"a six-month cure period"

A cure period is a set amount of time given to a borrower, counterparty, or contracting party to fix a missed payment, breach, or other problem before more serious consequences—like penalties, higher interest, or contract termination—kick in. For investors, it matters because it creates a short grace window that can prevent immediate losses and influence the timing and likelihood of recovery; think of it like a few extra days to pay a bill before a service is cut off.

reverse stock split financial

"including, if necessary, a reverse stock split"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

minimum share price requirement regulatory

"regain compliance with the minimum share price requirement"

A minimum share price requirement is a rule set by a stock exchange or regulator that a company’s stock must trade above a specific per-share price (usually measured as an average over a set period) to remain listed. Think of it like a minimum size needed to keep a product on a store shelf: if the stock trades below the threshold for too long, the company may face warnings, delisting procedures, or be asked to take corrective steps, which can affect liquidity and investor perception.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did ACH receive an NYSE continued-listing notice?

Accendra Health received the notice because its common stock’s average closing price was below $1.00 per share over a consecutive 30 trading-day period. The notice does not immediately affect the stock’s NYSE listing.

What does ACH need to do to regain NYSE compliance?

Accendra Health may regain compliance during the six-month cure period if, on the last trading day of a calendar month during that period or on its final day, the stock closes at least $1.00 per share and its average closing price over the 30 trading-day period ending that day is also at least $1.00.

Is Accendra Health considering a reverse stock split?

Accendra Health is considering alternatives, including, if necessary, a reverse stock split. The split would be subject to stockholder approval no later than the company’s next annual meeting, anticipated to take place in May 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/09/2026 - 04:10 PM Accepted by SEC EDGAR 10/09/2026 - 04:10 PM Learn about SEC filing dates

0000075252false00000752522026-10-062026-10-06

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 6, 2026

Accendra Health, Inc.

(Exact name of registrant as specified in its charter)

​

​ ​ ​	​	​
Virginia	001-09810	54-1701843
(State or other jurisdiction of	(Commission	(I.R.S. Employer
incorporation or organization)	File Number)	Identification No.)
​	​	​
4435 Waterfront Drive, Suite 300, Glen Allen, Virginia	​	23060
(Address of principal executive	​	​
offices)	​	(Zip Code)
​	​	​

​

Registrant’s telephone number, including area code (804) 277-4304

Securities registered pursuant to Section 12(b) of the Act:

​

​	​	​	​	​
Title of each class	​ ​ ​	Trading Symbol(s)	​ ​ ​	Name of each exchange on which registered
Common Stock, $2 par value per share	​	ACH	​	New York Stock Exchange

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.below):

​

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company         ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.          ◻

​

​

​

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On October 6, 2026 Accendra Health, Inc. (the “Company”) received notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it was not in compliance with the continued listing standard set forth in Section 802.01C of the NYSE’s Listed Company Manual (“Section 802.01C”) because the average closing price of the Company’s Common Stock (the “Common Stock”) was less than $1.00 per share over a consecutive 30 trading-day period. The Notice has no immediate impact on the listing of the Common Stock on the NYSE, subject to the Company’s compliance with the NYSE’s other continued listing requirements.

​

The Company intends to consider a number of available alternatives to cure its non-compliance with the applicable price criteria in the NYSE’s continued listing standards. Pursuant to Section 802.01C, the Company has a period of six months following the receipt of the Notice to regain compliance with the minimum share price requirement. The Company may regain compliance at any time during the six-month cure period if, on the last trading day of any calendar month during the six-month cure period or on the last day of the cure period, the Common Stock has a closing price of at least $1.00 per share and an average closing price of at least $1.00 per share over the 30 trading-day period ending on the last trading day of that month.

​

Section 802.01C requires the Company to notify the NYSE, within 10 business days of receipt of the Notice, of its intent to cure this deficiency. The Company intends to notify the NYSE of its intent to regain compliance with the requirements of Section 802.01C.

​

The Notice does not affect the Company’s business operations or its reporting obligations with the Securities and Exchange Commission.

​

Item 7.01. Regulation FD Disclosure.

On October 9, 2026, the Company issued a press release related to the foregoing. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

​

The information in Exhibit 99.1 is being furnished pursuant to Item 7.01 of Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

​

(d) Exhibits.

The following materials are filed as exhibits to this Current Report on Form 8-K.

Exhibit Number		Description
99.1		Press Release of the Company, dated October 9, 2026 (furnished pursuant to Item 7.01).
104		Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

​

​	​	​	​
​	​ ACCENDRA HEALTH, INC. ​
​	​
October 9, 2026	​	/s/ Jonathan A. Leon
​	​	​	Jonathan A. Leon
​	​	​	Executive Vice President and Chief Financial Officer

​

Exhibit 99.1

Accendra Health Receives Continued Listing Standard Notice from NYSE;

Intends to Cure Deficiency and Return to Compliance with NYSE Listing Standard

​

RICHMOND, VA – October 9, 2026 – Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that on October 6, 2026, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with the NYSE’s continued listing standards because, the average closing price of the Company’s Class A Common Stock (the “Common Stock”) was less than $1.00 per share over a consecutive 30 trading-day period. The Notice does not result in the immediate delisting of the Company’s Common Stock from the NYSE.

​

The Company intends to respond to the NYSE within ten business days of receipt of the Notice affirming its intent to cure the deficiency. Pursuant to the NYSE’s rules, the Company has a six-month period following receipt of the Notice to regain compliance with the NYSE’s minimum share price requirement.

​

The Company intends to consider a number of available alternatives to cure its non-compliance with the applicable price criteria in the NYSE’s continued listing standards including, if necessary, a reverse stock split that would be subject to stockholder approval no later than at the Company’s next annual meeting of stockholders anticipated to take place in May 2027. The Company can regain compliance with the minimum share price requirement at any time during the six-month cure period if, on the last trading day of any calendar month during the cure period or on the last day of the cure period, the Company has (i) a closing share price of at least $1.00, and (ii) an average closing share price of at least $1.00 over the 30 trading-day periods ending on the last trading day of that month.

​

The Company’s Common Stock will continue to be listed and trade on the NYSE during this period, subject to its compliance with other NYSE continued listing standards. The receipt of the Notice does not affect the Company’s business, operations or reporting requirements with the Securities and Exchange Commission.

​

Safe Harbor

This release is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public in compliance with the SEC’s Fair Disclosure Regulation. This release contains certain “forward looking” statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the Company’s ability to maintain the listing of its Common Stock on the NYSE, its intentions regarding regaining compliance with the minimum price condition of NYSE, the Company’s intended methods to cure such related deficiency, its ability to create shareholder value, and stock price expectations, as well as the Company’s anticipated future prospects and performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those projected or contemplated in the forward-looking statements. Investors should refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 20, 2026, including the section captioned “Item 1A. Risk Factors,” as applicable, and subsequent quarterly reports on Form 10-Q and current reports on Form 8-K filed with or furnished to the SEC, for a discussion of certain known risk factors that could cause the Company’s actual results to differ materially from its current estimates. These filings are available at www.accendrahealth.com. Given these risks and uncertainties, the Company can give no assurance that any forward-looking statements will, in fact, transpire and, therefore, cautions investors not to place undue reliance on them. The Company specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

​

​

1

About Accendra Health

Accendra Health, Inc. (NYSE: ACH) is a leading nationwide provider of products, technology, and services that support health beyond the hospital for millions of people each year. We connect patients, providers, and insurers, delivering innovative solutions that help promote better health outcomes and improve quality of life for people living with chronic, complex health conditions. Backed by the industry-leading expertise of our Apria and Byram brands, Accendra Health is reimagining the future of home-based care. To learn more about our broad portfolio of essentials for diabetes, sleep health, wound care, respiratory care, urology, and ostomy, visit www.accendrahealth.com.

​

​

​

CONTACTS

Investors

Will Parrish

Vice President, Strategy, Corporate Development, & Investor Relations

Investor.Relations@accendra.com

​

Media

Darla Turner

media@accendra.com

ACH-CORP

ACH-IR

SOURCE: Accendra Health, Inc.

2

Filing Exhibits & Attachments

5 documents

Press Releases

• EX-99.1 EX-99.1 11.7 KB

Other Documents

• EX-101 EX-101.SCH 3.4 KB
• EX-101 EX-101.DEF 2.8 KB
• EX-101 EX-101.LAB 19.7 KB
• EX-101 EX-101.PRE 10.8 KB